Different serological assays measuring anti–SARS-CoV-2 antibodies and their neutralizing activity in samples from individuals with severe and mild COVID-19 are compared.

Elusive, pharmacologically relevant conformation of the herpesvirus fusion protein is revealed by a multi-methodological approach.

Unmasking class II membrane fusion: Rift Valley fever virus (RVFV) is transmitted by mosquitos and enters cells through receptormediated endocytosis. The infection process requires class II membrane fusion proteins, which insert a hydrophobic fusion loop into cell membranes and then refold. Guardado-Calvo et al. report the high-resolution crystal structure of RVFV class II fusion protein Gc in its postfusion form complexed with phosphatidylcholine. They find that Gc does not restructure its fusion loop after insertion. Rather, it uses an integrated system that accommodates glycerophospholipid head groups and then initiates membrane reorganization by concentrating cholesterol at the insertion site. Comparison with class II fusion proteins from other virus families suggests a common mechanism, which may provide a target for future antiviral therapies. Science , this issue p. 663

Memory B-cell and antibody responses to the SARS-CoV-2 spike protein contribute to long-term immune protection against severe COVID-19, which can also be prevented by antibody-based interventions. Here, wide SARS-CoV-2 immunoprofiling in Wuhan COVID-19 convalescents combining serological, cellular, and monoclonal antibody explorations revealed humoral immunity coordination. Detailed characterization of a hundred SARS-CoV-2 spike memory B-cell monoclonal antibodies uncovered diversity in their repertoire and antiviral functions. The latter were influenced by the targeted spike region with strong Fc-dependent effectors to the S2 subunit and potent neutralizers to the receptor-binding domain. Amongst those, Cv2.1169 and Cv2.3194 antibodies cross-neutralized SARS-CoV-2 variants of concern, including Omicron BA.1 and BA.2. Cv2.1169, isolated from a mucosa-derived IgA memory B cell demonstrated potency boost as IgA dimers and therapeutic efficacy as IgG antibodies in animal models. Structural data provided mechanistic clues to Cv2.1169 potency and breadth. Thus, potent broadly neutralizing IgA antibodies elicited in mucosal tissues can stem SARS-CoV-2 infection, and Cv2.1169 and Cv2.3194 are prime candidates for COVID-19 prevention and treatment.